Application progress of drug-loaded microspheres embolization therapy in the clinical full-process management of hepatocellular carcinoma
10.3969/j.issn.1008-794X.2024.08.021
- VernacularTitle:载药微球栓塞治疗在肝癌全程管理中的临床应用进展
- Author:
Di WU
1
;
Lin ZHENG
Author Information
1. 450008 河南郑州 郑州大学附属肿瘤医院/河南省肿瘤医院微创介入科
- Keywords:
hepatocellular carcinoma;
drug-eluting bead;
transarterial chemoembolization;
interventional therapy
- From:
Journal of Interventional Radiology
2024;33(8):921-927
- CountryChina
- Language:Chinese
-
Abstract:
Drug-eluting beads transarterial chemoembolization(DEB-TACE)is a technique that uses drug-loading microspheres as the embolization agents in performing TACE.These microspheres can not only cause a permanent embolization of targeted blood vessels but also release the loaded chemotherapy drugs slowly,producing a sustained therapeutic effect on the targeted lesions.For recent years,DEB-TACE has demonstrated that it carries important role in the clinical treatment of all stages of hepatocellular carcinoma(HCC).For early-stage HCC,DEB-TACE can be used as an alternative therapy to surgery for the treatment of＞3 cm blood-rich HCC that cannot be surgically removed or ablated.DEB-TACE may also be used as a bridging therapy before liver transplantation.For early-stage large HCC and medium-stage HCC carrying the possibility of potential radical cure,DEB-TACE can rapidly reduce the active tumor volume,and the subsequent combination ablation therapy is expected to radically cure the patient's tumor.For unresectable intermediate-stage and advanced-stage HCC,the combination of DEB-TACE plus targeted and immunotherapeutic agents,which carries the effect of three complementary advantages,can strengthen the short-term efficacy and prolong the survival time of patients.Precision DEB-TACE combined with HAIC treatment is expected to become a new means of interventional therapy for patients with advanced HCC.
